Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial

Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54(1):87-95.

Publication Type:

Journal Article

Authors:

Takehara, T; Sakamoto, N; Nishiguchi, S; et, al

Source:

J Gastroenterol, Volume 54, Issue 1, p.87-95 (2019)

Cited On:

Patients With Decompensated Cirrhosis

Export Citation:

RIS Format

Top